Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resimmune with Radiation and Pembrolizumab in Stage IV Melanoma
NCT02990416Phase 2Unknown
- Sponsor
- Angimmune LLC
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Immunotoxins, Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of A-dmDT390-bisFv(UCHT1) in melanoma, sponsored by Angimmune LLC. Status: unknown.
02
Drugs
A-dmDT390-bisFv(UCHT1)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02990416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02990416.